glp-1 and parkinson's disease disease(PD)is pathologically characterized by abnormal accumulation of α-synuclein fibers(Lewy bodies) in the substantia nigra other brain regions.🧠Triple-hit hypothesis of gut microbiota in PD.(Blue pathway)👉🏻First,Akkermansia,which GLP-1 and Parkinson's Disease: Research,

IRB approval status: This study was conducted after receiving the Institutional Review Board approval from King Abdullah International Medical Research Center (protocol number: NRJ24/016/10)

Bonner C, Kerr-Conte J, Gmyr V, et al

Additionally, the Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity trial demonstrated that semaglutide consistently reduced major cardiovascular event endpoints by approximately 20% compared to placebo over an approximately 3-year follow-up period in patients with overweight or obesity and cardiovascular disease (Table 1), but without diabetes [93]

J Biol Dyn

The Importance of Rotating Sites It might be tempting to find one perfect spot and use it every week, but this is a mistake

Rather than partnering with Novo on semaglutide, which is now copyable, Cipla partnered with Eli Lilly on tirzepatide, launching Yurpeak in India in late 2025